This section is intended for patients prescribed ADCETRIS in Great Britain. If you are a member of the public in Great Britain click here. If you are a GB healthcare professional click here.


ADCETRIS has received a conditional marketing authorisation. This means that there is more evidence to come, especially about the long term effects. Every year the agency that reviews medicines in Great Britain will review any new information that is available. You will be informed if any of this new information affects your treatment with brentuximab vedotin.

ADCETRIS, also known as brentuximab vedotin, is used to treat adults with Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (sALCL), or cutaneous T-cell lymphoma (CTCL). You have been prescribed brentuximab vedotin to treat either:1

Hodgkin lymphoma that has:

  • come back after or not responded to a stem cell transplant, or
  • come back after or not responded to at least two previous anti-cancer treatments and where you cannot receive additional combination anti-cancer treatments or have a stem cell transplant or
  • an increased risk of coming back after a transplant of your own stem cells

Systemic Anaplastic Large Cell Lymphoma that has:

  • been newly diagnosed and is untreated
  • come back after or not responded to previous anti-cancer treatments

Cutaneous T-cell lymphoma that has:

  • come back after or not responded to at least one anti-cancer medicine that travels through the bloodstream

This section of the website has been provided for patients prescribed brentuximab vedotin. It explains how it works, how it is administered and the possible side effects you may experience.

This website does not replace your healthcare professional's advice - always ask your doctor, nurse or pharmacist any questions you might have about your treatment or disease.

About ADCETRIS (brentuximab vedotin)

Brentuximab vedotin is a monoclonal antibody linked to an anti-cancer agent, which kills cancer cells.

Receiving ADCETRIS (brentuximab vedotin)

Brentuximab vedotin is given to you by your doctor or nurse as an infusion into a vein (intravenously).


You should be aware of the signs and symptoms of possible severe adverse reactions to brentuximab vedotin.

Practical advice and support

Takeda has a number of tools to help you manage your treatment and stay on top of symptoms and side effects.

C-ANPROM/UK/ADCE/0027 - December 2021

ADCETRIS (brentuximab vedotin) is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects whilst taking ADCETRIS, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the patient information leaflet.

You can also report side effects directly via the Yellow Card Scheme at

By reporting side effects you can help provide more information on the safety of this medicine.